A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis

1.

Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378:169–80. https://doi.org/10.1056/NEJMra1401483.CrossRefPubMedPubMedCentral

2.

Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–73. https://doi.org/10.1016/S1474-4422(17)30470-2.CrossRefPubMed

3.

Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129:606–16. https://doi.org/10.1093/brain/awl007.CrossRefPubMed

4.

Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907–11. https://doi.org/10.1212/wnl.46.4.907.CrossRefPubMed

5.

Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321:175–87. https://doi.org/10.1001/jama.2018.20588.CrossRefPubMedPubMedCentral

6.

Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76:536–41. https://doi.org/10.1001/jamaneurol.2018.4905.CrossRefPubMedPubMedCentral

7.

Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–60. https://doi.org/10.1016/S1474-4422(09)70021-3.CrossRefPubMed

8.

Havrdova E, Arnold DL, Bar-Or A, et al. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Mult Scler J Exp Transl Clin. 2018;4:2055217318760642. https://doi.org/10.1177/2055217318760642.CrossRefPubMedPubMedCentral

9.

Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130:1089–104. https://doi.org/10.1093/brain/awm038.CrossRefPubMed

10.

Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011;134:2755–71. https://doi.org/10.1093/brain/awr182.CrossRefPubMed

11.

Magliozzi R, Howell OW, Reeves C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010;68:477–93. https://doi.org/10.1002/ana.22230.CrossRefPubMed

12.

Jackle K, Zeis T, Schaeren-Wiemers N, et al. Molecular signature of slowly expanding lesions in progressive multiple sclerosis. Brain. 2020;143:2073–88. https://doi.org/10.1093/brain/awaa158.CrossRefPubMed

13.

Calvi A, Carrasco FP, Tur C, et al. Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis. Neurology. 2022. https://doi.org/10.1212/WNL.0000000000200144.CrossRefPubMed

14.

Preziosa P, Pagani E, Meani A, et al. Slowly expanding lesions predict 9-year multiple sclerosis disease progression. Neurol Neuroimmunol Neuroinflamm. 2022. https://doi.org/10.1212/NXI.0000000000001139.CrossRefPubMedPubMedCentral

15.

Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 2009;8:280–91. https://doi.org/10.1016/S1474-4422(09)70043-2.CrossRefPubMed

16.

Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1–13. https://doi.org/10.1042/BJ20081386.CrossRefPubMed

17.

Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14:183–93. https://doi.org/10.1016/S1474-4422(14)70256-X.CrossRefPubMed

18.

Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: mechanisms and immunotherapy. Neuron. 2018;97:742–68. https://doi.org/10.1016/j.neuron.2018.01.021.CrossRefPubMed

19.

Maghzi AH, Minagar A, Waubant E. Neuroprotection in multiple sclerosis: a therapeutic approach. CNS Drugs. 2013;27:799–815. https://doi.org/10.1007/s40263-013-0093-7.CrossRefPubMed

20.

Hametner S, Wimmer I, Haider L, Pfeifenbring S, Bruck W, Lassmann H. Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol. 2013;74:848–61. https://doi.org/10.1002/ana.23974.CrossRefPubMedPubMedCentral

21.

Micu I, Plemel JR, Caprariello AV, Nave KA, Stys PK. Axo-myelinic neurotransmission: a novel mode of cell signalling in the central nervous system. Nat Rev Neurosci. 2018;19:49–58. https://doi.org/10.1038/nrn.2017.128.CrossRefPubMed

22.

Greene C, Campbell M. Tight junction modulation of the blood brain barrier: CNS delivery of small molecules. Tissue Barriers. 2016;4:e1138017. https://doi.org/10.1080/21688370.2015.1138017.CrossRefPubMedPubMedCentral

23.

Banks WA. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 2009;9(Suppl 1):S3. https://doi.org/10.1186/1471-2377-9-S1-S3.CrossRefPubMedPubMedCentral

24.

Yong HYF, Yong VW. Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis. Nat Rev Neurol. 2021. https://doi.org/10.1038/s41582-021-00581-x.CrossRefPubMed

25.

Spencer JI, Bell JS, DeLuca GC. Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier. J Neurol Neurosurg Psychiatry. 2018;89:42–52. https://doi.org/10.1136/jnnp-2017-316011.CrossRefPubMed

26.

Alvarez JI, Cayrol R, Prat A. Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta. 2011;1812:252–64. https://doi.org/10.1016/j.bbadis.2010.06.017.CrossRefPubMed

27.

Pun PB, Lu J, Moochhala S. Involvement of ROS in BBB dysfunction. Free Radic Res. 2009;43:348–64. https://doi.org/10.1080/10715760902751902.CrossRefPubMed

28.

Jolivel V, Luessi F, Masri J, et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain. 2013;136:1048–66. https://doi.org/10.1093/brain/awt023.CrossRefPubMed

29.

Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008;71:1261–7. https://doi.org/10.1212/01.wnl.0000327609.57688.ea.CrossRefPubMed

30.

Mitosek-Szewczyk K, Stelmasiak Z, Bartosik-Psujek H, Belniak E. Impact of cladribine on soluble adhesion molecules in multiple sclerosis. Acta Neurol Scand. 2010;122:409–13. https://doi.org/10.1111/j.1600-0404.2010.01330.x.CrossRefPubMed

31.

Rammohan K, Coyle PK, Sylvester E, et al. The development of cladribine tablets for the treatment of multiple sclerosis: a comprehensive review. Drugs. 2020;80:1901–28. https://doi.org/10.1007/s40265-020-01422-9.CrossRefPubMedPubMedCentral

32.

Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler. 2005;11:425–32. https://doi.org/10.1191/1352458505ms1190oa.CrossRefPubMed

33.

Wegner C, Stadelmann C, Pfortner R, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;227:133–43. https://doi.org/10.1016/j.jneuroim.2010.07.009.CrossRefPubMed

34.

Xu J, Kim GM, Ahmed SH, et al. Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury. J Neurosci. 2001;21:92–7.CrossRef

35.

Balasa R, Barcutean L, Mosora O, Manu D. Reviewing the significance of blood-brain barrier disruption in multiple sclerosis pathology and treatment. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22168370.CrossRefPubMedPubMedCentral

36.

Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat Rev Drug Discov. 2019;18:905–22. https://doi.org/10.1038/s41573-019-0035-2.CrossRefPubMed

37.

Gold R, Linker RA, Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin Immunol. 2012;142:44–8. https://doi.org/10.1016/j.clim.2011.02.017.CrossRefPubMed

38.

Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci. 2013;328:9–18. https://doi.org/10.1016/j.jns.2013.02.011.CrossRefPubMedPubMedCentral

39.

Mills EA, Ogrodnik MA, Plave A, Mao-Draayer Y. Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis. Front Neurol. 2018;9:5. https://doi.org/10.3389/fneur.2018.00005.CrossRefPubMedPubMedCentral

40.

Rejdak K, Stelmasiak Z, Grieb P. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study. Mult Scler Relat Disord. 2019;27:117–20. https://doi.org/10.1016/j.msard.2018.10.006.CrossRefPubMed

41.

Wipke BT, Hoepner R, Strassburger-Krogias K, et al. Different fumaric acid esters elicit distinct pharmacologic responses. Neurol Neuroimmunol Neuroinflamm. 2021. https://doi.org/10.1212/NXI.0000000000000950.CrossRefPubMedPubMedCentral

42.

Briard E, Rudolph B, Desrayaud S, Krauser JA, Auberson YP. MS565: a SPECT tracer for evaluating the brain penetration of BAF312 (Siponimod). ChemMedChem. 2015;10:1008–18. https://doi.org/10.1002/cmdc.201500115.CrossRefPubMed

43.

Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet. 1997;32:120–31. https://doi.org/10.2165/00003088-199732020-00003.CrossRefPubMed

44.

Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77:1132–40. https://doi.org/10.1001/jamaneurol.2020.1568.CrossRefPubMed

45.

Wolinsky JS, Montalban X, Hauser SL, et al. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Ann Neurol. 2018;84:527–36. https://doi.org/10.1002/ana.25313.CrossRefPubMedPubMedCentral

46.

Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209–20. https://doi.org/10.1056/NEJMoa1606468.CrossRefPubMed

47.

Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81:857–70. https://doi.org/10.1002/ana.24954.CrossRefPubMedPubMedCentral

48.

Siller N, Kuhle J, Muthuraman M, et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler. 2019;25:678–86. https://doi.org/10.1177/1352458518765666.CrossRefPubMed

49.

Barro C, Benkert P, Disanto G, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. 2018;141:2382–91. https://doi.org/10.1093/brain/awy154.CrossRefPubMed

50.

Canto E, Barro C, Zhao C, et al. Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. JAMA Neurol. 2019;76:1359–66. https://doi.org/10.1001/jamaneurol.2019.2137.CrossRefPubMedPubMedCentral

51.

Chitnis T, Gonzalez C, Healy BC, et al. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol. 2018;5:1478–91. https://doi.org/10.1002/acn3.638.CrossRefPubMedPubMedCentral

52.

Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004;63:1586–90. https://doi.org/10.1212/01.wnl.0000142988.49341.d1.CrossRefPubMed

53.

Hogel H, Rissanen E, Barro C, et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler. 2020;26:210–9. https://doi.org/10.1177/1352458518819380.CrossRefPubMed

54.

Huss A, Otto M, Senel M, Ludolph AC, Abdelhak A, Tumani H. A score based on NfL and glial markers may differentiate between relapsing-remitting and progressive MS course. Front Neurol. 2020;11:608. https://doi.org/10.3389/fneur.2020.00608.CrossRefPubMedPubMedCentral

55.

Giarraputo J, Giamberardino S, Arvai S, et al. Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis. J Neuroimmunol. 2021;354:577541. https://doi.org/10.1016/j.jneuroim.2021.577541.CrossRefPubMed

56.

Ontaneda D, Fox RJ. Imaging as an outcome measure in multiple sclerosis. Neurotherapeutics. 2017;14:24–34. https://doi.org/10.1007/s13311-016-0479-6.CrossRefPubMed

57.

Luchicchi A, Hart B, Frigerio I, et al. Axon-myelin unit blistering as early event in MS normal appearing white matter. Ann Neurol. 2021;89:711–25. https://doi.org/10.1002/ana.26014.CrossRefPubMedPubMedCentral

58.

Meca-Lallana V, Berenguer-Ruiz L, Carreres-Polo J, et al. Deciphering multiple sclerosis progression. Front Neurol. 2021;12:608491. https://doi.org/10.3389/fneur.2021.608491.CrossRefPubMedPubMedCentral

59.

Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain. 2002;125:1676–95. https://doi.org/10.1093/brain/awf177.CrossRefPubMed

60.

Germana S, Shinohara N. Qa-1/Tla region alloantigen-specific CTL with alpha beta receptor. Immunology. 1991;74:578–82.PubMedPubMedCentral

61.

Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20:653–70. https://doi.org/10.1016/S1474-4422(21)00095-8.CrossRefPubMed

62.

Kaunzner UW, Gauthier SA. MRI in the assessment and monitoring of multiple sclerosis: an update on best practice. Ther Adv Neurol Disord. 2017;10:247–61. https://doi.org/10.1177/1756285617708911.CrossRefPubMedPubMedCentral

63.

Amato MP, Portaccio E, Goretti B, et al. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol. 2007;64:1157–61. https://doi.org/10.1001/archneur.64.8.1157.CrossRefPubMed

64.

Eshaghi A, Prados F, Brownlee WJ, et al. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol. 2018;83:210–22. https://doi.org/10.1002/ana.25145.CrossRefPubMedPubMedCentral

65.

Song X, Li D, Qiu Z, et al. Correlation between EDSS scores and cervical spinal cord atrophy at 3T MRI in multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord. 2020;37:101426. https://doi.org/10.1016/j.msard.2019.101426.CrossRefPubMed

66.

Eijlers AJC, Dekker I, Steenwijk MD, et al. Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis. Neurology. 2019;93:e1348–59. https://doi.org/10.1212/WNL.0000000000008198.CrossRefPubMed

67.

Mina Y, Azodi S, Dubuche T, et al. Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: quantification and correlation with clinical disability. Neuroimage Clin. 2021;30:102680. https://doi.org/10.1016/j.nicl.2021.102680.CrossRefPubMedPubMedCentral

68.

Kearney H, Miszkiel KA, Yiannakas MC, Altmann DR, Ciccarelli O, Miller DH. Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis. Mult Scler. 2016;22:910–20. https://doi.org/10.1177/1352458515604905.CrossRefPubMed

69.

Houtchens MK, Benedict RH, Killiany R, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology. 2007;69:1213–23. https://doi.org/10.1212/01.wnl.0000276992.17011.b5.CrossRefPubMed

70.

Schoonheim MM, Pinter D, Prouskas SE, et al. Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy. Mult Scler. 2022;28:61–70. https://doi.org/10.1177/13524585211008743.CrossRefPubMed

71.

Bhargava P, Kim S, Reyes AA, et al. Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition. Brain. 2021;144:1396–408. https://doi.org/10.1093/brain/awab045.CrossRefPubMedPubMedCentral

72.

Dal-Bianco A, Grabner G, Kronnerwetter C, et al. Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol. 2017;133:25–42. https://doi.org/10.1007/s00401-016-1636-z.CrossRefPubMed

73.

Cortese R, Collorone S, Ciccarelli O, Toosy AT. Advances in brain imaging in multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1756286419859722. https://doi.org/10.1177/1756286419859722.CrossRefPubMedPubMedCentral

74.

Elliott C, Wolinsky JS, Hauser SL, et al. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Mult Scler. 2019;25:1915–25. https://doi.org/10.1177/1352458518814117.CrossRefPubMed

75.

Campanholo KR, Pitombeira MS, Rimkus CM, et al. Myelin imaging measures as predictors of cognitive impairment in MS patients: a hybrid PET-MRI study. Mult Scler Relat Disord. 2022;57:103331. https://doi.org/10.1016/j.msard.2021.103331.CrossRefPubMed

76.

Kolasa M, Hakulinen U, Brander A, et al. Diffusion tensor imaging and disability progression in multiple sclerosis: a 4-year follow-up study. Brain Behav. 2019;9:e01194. https://doi.org/10.1002/brb3.1194.CrossRefPubMed

77.

Edwards EM, Wu W, Fritz NE. Using myelin water imaging to link underlying pathology to clinical function in multiple sclerosis: a scoping review. Mult Scler Relat Disord. 2022;59:103646. https://doi.org/10.1016/j.msard.2022.103646.CrossRefPubMed

78.

Rudick RA, Fisher E, Lee JC, Duda JT, Simon J. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler. 2000;6:365–72. https://doi.org/10.1177/135245850000600601.CrossRefPubMed

79.

Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006;67:944–53. https://doi.org/10.1212/01.wnl.0000237994.95410.ce.CrossRefPubMed

80.

Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:1489–96. https://doi.org/10.1016/S0140-6736(04)17271-1.CrossRefPubMed

81.

De Stefano N, Comi G, Kappos L, et al. Efficacy of subcutaneous interferon beta-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry. 2014;85:647–53. https://doi.org/10.1136/jnnp-2013-306289.CrossRefPubMed

82.

Rovaris M, Comi G, Rocca MA, et al. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. Mult Scler. 2007;13:502–8. https://doi.org/10.1177/1352458506070704.CrossRefPubMed

83.

Khan O, Shen Y, Caon C, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler. 2005;11:646–51. https://doi.org/10.1191/1352458505ms1234oa.CrossRefPubMed

84.

Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology. 2000;54:813–7. https://doi.org/10.1212/wnl.54.4.813.CrossRefPubMed

85.

Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503–11. https://doi.org/10.1016/S0140-6736(09)61259-9.CrossRefPubMed

86.

Comi G, Martinelli V, Rodegher M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler. 2013;19:1074–83. https://doi.org/10.1177/1352458512469695.CrossRefPubMed

87.

O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293–303. https://doi.org/10.1056/NEJMoa1014656.CrossRefPubMed

88.

Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:977–86. https://doi.org/10.1016/S1474-4422(14)70191-7.CrossRefPubMed

89.

Wolinsky JS, Narayana PA, Nelson F, et al. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler. 2013;19:1310–9. https://doi.org/10.1177/1352458513475723.CrossRefPubMed

90.

Sprenger T, Kappos L, Radue EW, et al. Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide. Mult Scler. 2020;26:1207–16. https://doi.org/10.1177/1352458519855722.CrossRefPubMed

91.

Radue EW, Sprenger T, Gaetano L, et al. Teriflunomide slows BVL in relapsing MS: a reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm. 2017;4:e390. https://doi.org/10.1212/NXI.0000000000000390.CrossRefPubMedPubMedCentral

92.

Miller DH, Fox RJ, Phillips JT, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015;84:1145–52. https://doi.org/10.1212/WNL.0000000000001360.CrossRefPubMedPubMedCentral

93.

Arnold DL, Gold R, Kappos L, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 DEFINE study. J Neurol. 2014;261:1794–802. https://doi.org/10.1007/s00415-014-7412-x.CrossRefPubMedPubMedCentral

94.

Dupuy SL, Tauhid S, Hurwitz S, Chu R, Yousuf F, Bakshi R. The effect of dimethyl fumarate on cerebral gray matter atrophy in multiple sclerosis. Neurol Ther. 2016;5:215–29. https://doi.org/10.1007/s40120-016-0054-4.CrossRefPubMedPubMedCentral

95.

De Stefano N, Silva DG, Barnett MH. Effect of fingolimod on brain volume loss in patients with multiple sclerosis. CNS Drugs. 2017;31:289–305. https://doi.org/10.1007/s40263-017-0415-2.CrossRefPubMedPubMedCentral

96.

Gaetano L, Haring DA, Radue EW, et al. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis. Neurology. 2018;90:e1324–32. https://doi.org/10.1212/WNL.0000000000005292.CrossRefPubMed

97.

Preziosa P, Rocca MA, Pagani E, et al. Two-year regional grey and white matter volume changes with natalizumab and fingolimod. J Neurol Neurosurg Psychiatry. 2020;91:493–502. https://doi.org/10.1136/jnnp-2019-322439.CrossRefPubMed

98.

Zivadinov R, Hojnacki D, Bergsland N, et al. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years. Eur J Neurol. 2016;23:1101–9. https://doi.org/10.1111/ene.12992.CrossRefPubMed

99.

Sastre-Garriga J, Tur C, Pareto D, et al. Brain atrophy in natalizumab-treated patients: a 3-year follow-up. Mult Scler. 2015;21:749–56. https://doi.org/10.1177/1352458514556300.CrossRefPubMed

100.

Iaffaldano P, Viterbo RG, Trojano M. Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients. J Neurol. 2016;263:1620–5. https://doi.org/10.1007/s00415-016-8177-1.CrossRefPubMed

101.

Talmage GD, Coppes OJM, Javed A, Bernard J. Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: a prospective, non-randomized pilot study. PLoS One. 2017;12:e0173299. https://doi.org/10.1371/journal.pone.0173299.CrossRefPubMedPubMedCentral

102.

Arnold DS, Sprenger T, Bar-Or A, et al. Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I/II and ORATORIO. In: 8th joint ACTRIMS-ECTRIMS meeting 2020, platform presentation number #FC03.05.

103.

Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391:1263–73. https://doi.org/10.1016/S0140-6736(18)30475-6.CrossRefPubMed

104.

Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–34. https://doi.org/10.1056/NEJMoa1601277.CrossRefPubMed

105.

Butzkueven H, Spelman T, Horakova D, et al. Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry. Eur J Neurol. 2021. https://doi.org/10.1111/ene.14824.CrossRefPubMedPubMedCentral

106.

Gajofatto A. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date. Drug Des Devel Ther. 2017;11:3153–7. https://doi.org/10.2147/DDDT.S122249.CrossRefPubMedPubMedCentral

107.

Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1075–84. https://doi.org/10.1016/S0140-6736(15)01314-8.CrossRefPubMed

108.

Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of Bruton’s tyrosine kinase in immunodeficient XID mice. Science. 1993;261:358–61. https://doi.org/10.1126/science.8332901.CrossRefPubMed

109.

Carnero Contentti E, Correale J. Bruton’s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis. Expert Opin Emerg Drugs. 2020;25:377–81. https://doi.org/10.1080/14728214.2020.1822817.CrossRefPubMed

110.

Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14:219–32. https://doi.org/10.1038/nrc3702.CrossRefPubMed

111.

Mangla A, Khare A, Vineeth V, et al. Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood. 2004;104:1191–7. https://doi.org/10.1182/blood-2004-01-0207.CrossRefPubMed

112.

Neys SFH, Rip J, Hendriks RW, Corneth OBJ. Bruton’s tyrosine kinase inhibition as an emerging therapy in systemic autoimmune disease. Drugs. 2021;81:1605–26. https://doi.org/10.1007/s40265-021-01592-0.CrossRefPubMedPubMedCentral

113.

Martin E, Aigrot MS, Grenningloh R, et al. Bruton’s tyrosine kinase inhibition promotes myelin repair. Brain Plast. 2020;5:123–33. https://doi.org/10.3233/BPL-200100.CrossRefPubMedPubMedCentral

114.

Geladaris A, Hausler D, Weber MS. Microglia: the missing link to decipher and therapeutically control MS progression? Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22073461.CrossRefPubMedPubMedCentral

115.

Brullo C, Villa C, Tasso B, Russo E, Spallarossa A. Btk inhibitors: a medicinal chemistry and drug delivery perspective. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22147641.CrossRefPubMedPubMedCentral

116.

Menzfeld C, John M, van Rossum D, et al. Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism. Glia. 2015;63:1083–99. https://doi.org/10.1002/glia.22803.CrossRefPubMed

117.

Lewcock JW, Schlepckow K, Di Paolo G, Tahirovic S, Monroe KM, Haass C. Emerging microglia biology defines novel therapeutic approaches for Alzheimer’s disease. Neuron. 2020;108:801–21. https://doi.org/10.1016/j.neuron.2020.09.029.CrossRefPubMed

118.

International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019. https://doi.org/10.1126/science.aav7188.CrossRefPubMedCentral

119.

Hammond TR, Dufort C, Dissing-Olesen L, et al. Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. Immunity. 2019;50:253–271256. https://doi.org/10.1016/j.immuni.2018.11.004.CrossRefPubMed

120.

van Olst L, Rodriguez-Mogeda C, Picon C, et al. Meningeal inflammation in multiple sclerosis induces phenotypic changes in cortical microglia that differentially associate with neurodegeneration. Acta Neuropathol. 2021;141:881–99. https://doi.org/10.1007/s00401-021-02293-4.CrossRefPubMedPubMedCentral

121.

Miron VE, Boyd A, Zhao JW, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci. 2013;16:1211–8. https://doi.org/10.1038/nn.3469.CrossRefPubMedPubMedCentral

122.

Pinto MV, Fernandes A. Microglial phagocytosis-rational but challenging therapeutic target in multiple sclerosis. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21175960.CrossRefPubMedPubMedCentral

123.

Ronzano R, Roux T, Thetiot M, et al. Microglia-neuron interaction at nodes of Ranvier depends on neuronal activity through potassium release and contributes to remyelination. Nat Commun. 2021;12:5219. https://doi.org/10.1038/s41467-021-25486-7.CrossRefPubMedPubMedCentral

124.

Nam HY, Nam JH, Yoon G, et al. Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice. J Neuroinflamm. 2018;15:271. https://doi.org/10.1186/s12974-018-1308-0.CrossRef

125.

Keaney J, Gasser J, Gillet G, Scholz D, Kadiu I. Inhibition of Bruton’s tyrosine kinase modulates microglial phagocytosis: therapeutic implications for Alzheimer’s disease. J Neuroimmune Pharmacol. 2019;14:448–61. https://doi.org/10.1007/s11481-019-09839-0.CrossRefPubMedPubMedCentral

126.

Caldwell RD, Qiu H, Askew BC, et al. Discovery of evobrutinib: an oral, potent, and highly selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of immunological diseases. J Med Chem. 2019;62:7643–55. https://doi.org/10.1021/acs.jmedchem.9b00794.CrossRefPubMed

127.

Torke S, Pretzsch R, Hausler D, et al. Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease. Acta Neuropathol. 2020;140:535–48. https://doi.org/10.1007/s00401-020-02204-z.CrossRefPubMedPubMedCentral

128.

Montalban X, Arnold DL, Weber MS, et al. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N Engl J Med. 2019;380:2406–17. https://doi.org/10.1056/NEJMoa1901981.CrossRefPubMed

129.

Reich DS, Arnold DL, Vermersch P, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20:729–38. https://doi.org/10.1016/S1474-4422(21)00237-4.CrossRefPubMed

130.

Dhillon S. Orelabrutinib: first approval. Drugs. 2021;81:503–7. https://doi.org/10.1007/s40265-021-01482-5.CrossRefPubMed

131.

Weber H, Harp C, Goodyear A. Fenebrutinib reduces disease activity in a mouse model of inflammatory multiple sclerosis, which is associated with reduced microglial activation. In: ECTRIMS 2021 Abstract P680.

132.

Cohen S, Tuckwell K, Katsumoto TR, et al. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES Study). Arthritis Rheumatol. 2020. https://doi.org/10.1002/art.41275.CrossRefPubMedPubMedCentral

133.

Isenberg D, Furie R, Jones NS, et al. Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2021;73:1835–46. https://doi.org/10.1002/art.41811.CrossRefPubMed

134.

Metz M, Sussman G, Gagnon R, et al. Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. Nat Med. 2021;27:1961–9. https://doi.org/10.1038/s41591-021-01537-w.CrossRefPubMedPubMedCentral

135.

Zain R, Vihinen M. Structure–function relationships of covalent and non-covalent BTK inhibitors. Front Immunol. 2021;12:694853. https://doi.org/10.3389/fimmu.2021.694853.CrossRefPubMedPubMedCentral

136.

Gibson LC, Hastings SF, McPhee I, et al. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol. 2006;538:39–42. https://doi.org/10.1016/j.ejphar.2006.02.053.CrossRefPubMed

137.

Takuma K, Lee E, Enomoto R, Mori K, Baba A, Matsuda T. Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model. Br J Pharmacol. 2001;133:841–8. https://doi.org/10.1038/sj.bjp.0704146.CrossRefPubMedPubMedCentral

138.

Fujimoto T, Sakoda S, Fujimura H, Yanagihara T. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol. 1999;95:35–42. https://doi.org/10.1016/s0165-5728(98)00251-3.CrossRefPubMed

139.

Kagitani-Shimono K, Mohri I, Fujitani Y, et al. Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model. J Neuroinflamm. 2005;2:10. https://doi.org/10.1186/1742-2094-2-10.CrossRef

140.

Suzumura A, Ito A, Mizuno T. Phosphodiesterase inhibitors suppress IL-12 production with microglia and T helper 1 development. Mult Scler. 2003;9:574–8. https://doi.org/10.1191/1352458503ms970oa.CrossRefPubMed

141.

Pifarre P, Prado J, Giralt M, Molinero A, Hidalgo J, Garcia A. Cyclic GMP phosphodiesterase inhibition alters the glial inflammatory response, reduces oxidative stress and cell death and increases angiogenesis following focal brain injury. J Neurochem. 2010;112:807–17. https://doi.org/10.1111/j.1471-4159.2009.06518.x.CrossRefPubMed

142.

You T, Cheng Y, Zhong J, et al. Roflupram, a phosphodiesterase 4 inhibitor, suppresses inflammasome activation through autophagy in microglial cells. ACS Chem Neurosci. 2017;8:2381–92. https://doi.org/10.1021/acschemneuro.7b00065.CrossRefPubMed

143.

Li D, Xu J, Qin Y, Cai N, Cheng Y, Wang H. Roflupram, a novel phosphodiesterase 4 inhibitor, inhibits lipopolysaccharide-induced neuroinflammatory responses through activation of the AMPK/Sirt1 pathway. Int Immunopharmacol. 2021;90:107176. https://doi.org/10.1016/j.intimp.2020.107176.CrossRefPubMed

144.

Xie J, Bi B, Qin Y, et al. Inhibition of phosphodiesterase-4 suppresses HMGB1/RAGE signaling pathway and NLRP3 inflammasome activation in mice exposed to chronic unpredictable mild stress. Brain Behav Immun. 2021;92:67–77. https://doi.org/10.1016/j.bbi.2020.11.029.CrossRefPubMed

145.

Lambeng N, Michel PP, Agid Y, Ruberg M. The relationship between differentiation and survival in PC12 cells treated with cyclic adenosine monophosphate in the presence of epidermal growth factor or nerve growth factor. Neurosci Lett. 2001;297:133–6. https://doi.org/10.1016/s0304-3940(00)01690-6.CrossRefPubMed

146.

Sanftner LM, Gibbons JA, Gross MI, Suzuki BM, Gaeta FC, Johnson KW. Cross-species comparisons of the pharmacokinetics of ibudilast. Xenobiotica. 2009;39:964–77. https://doi.org/10.3109/00498250903254340.CrossRefPubMed

147.

Barkhof F, Hulst HE, Drulovic J, et al. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology. 2010;74:1033–40. https://doi.org/10.1212/WNL.0b013e3181d7d651.CrossRefPubMed

148.

Fox RJ, Coffey CS, Conwit R, et al. Phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med. 2018;379:846–55. https://doi.org/10.1056/NEJMoa1803583.CrossRefPubMedPubMedCentral

149.

Naismith RT, Bermel RA, Coffey CS, et al. Effects of ibudilast on MRI measures in the phase 2 SPRINT-MS study. Neurology. 2021;96:e491–500. https://doi.org/10.1212/WNL.0000000000011314.CrossRefPubMedPubMedCentral

150.

Fox RJ, Raska P, Barro C, et al. Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. Mult Scler. 2021;27:2014–22. https://doi.org/10.1177/1352458520986956.CrossRefPubMedPubMedCentral

151.

Sakaie K, Fedler JK, Yankey JW, et al. Influence of equipment changes on MRI measures of brain atrophy and brain microstructure in a placebo-controlled trial of ibudilast in progressive multiple sclerosis. Mult Scler J Exp Transl Clin. 2021;7:20552173211010844. https://doi.org/10.1177/20552173211010843.CrossRefPubMedPubMedCentral

152.

Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain. 2002;125:1297–308. https://doi.org/10.1093/brain/awf133.CrossRefPubMed

153.

Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci. 2001;21:2580–8.CrossRef

154.

Defaux A, Zurich MG, Honegger P, Monnet-Tschudi F. Minocycline promotes remyelination in aggregating rat brain cell cultures after interferon-gamma plus lipopolysaccharide-induced demyelination. Neuroscience. 2011;187:84–92. https://doi.org/10.1016/j.neuroscience.2011.04.053.CrossRefPubMed

155.

Maier K, Merkler D, Gerber J, et al. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol Dis. 2007;25:514–25. https://doi.org/10.1016/j.nbd.2006.10.022.CrossRefPubMed

156.

Planche V, Panatier A, Hiba B, et al. Selective dentate gyrus disruption causes memory impairment at the early stage of experimental multiple sclerosis. Brain Behav Immun. 2017;60:240–54. https://doi.org/10.1016/j.bbi.2016.11.010.CrossRefPubMed

157.

Di Filippo M, de Iure A, Giampa C, et al. Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis. Sci Rep. 2016;6:20926. https://doi.org/10.1038/srep20926.CrossRefPubMedPubMedCentral

158.

Chen X, Ma L, Jiang Y, et al. Minocycline up-regulates the expression of brain-derived neurotrophic factor and nerve growth factor in experimental autoimmune encephalomyelitis. Eur J Pharmacol. 2012;686:124–9. https://doi.org/10.1016/j.ejphar.2012.04.043.CrossRefPubMed

159.

Hou Y, Heon Ryu C, Jun JA, Kim SM, Jeong CH, Jeun SS. Interferon beta-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014;274:20–7. https://doi.org/10.1016/j.jneuroim.2014.06.001.CrossRefPubMed

160.

Chen X, Hu X, Zou Y, et al. Combined treatment with minocycline and prednisone attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. J Neuroimmunol. 2009;210:22–9. https://doi.org/10.1016/j.jneuroim.2009.02.016.CrossRefPubMed

161.

Chen X, Pi R, Liu M, et al. Combination of methylprednisolone and minocycline synergistically improves experimental autoimmune encephalomyelitis in C57 BL/6 mice. J Neuroimmunol. 2010;226:104–9. https://doi.org/10.1016/j.jneuroim.2010.05.039.CrossRefPubMed

162.

Giuliani F, Metz LM, Wilson T, Fan Y, Bar-Or A, Yong VW. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J Neuroimmunol. 2005;158:213–21. https://doi.org/10.1016/j.jneuroim.2004.09.006.CrossRefPubMed

163.

Garrido-Mesa N, Zarzuelo A, Galvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169:337–52. https://doi.org/10.1111/bph.12139.CrossRefPubMedPubMedCentral

164.

Metz LM, Zhang Y, Yeung M, et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol. 2004;55:756. https://doi.org/10.1002/ana.20111.CrossRefPubMed

165.

Zabad RK, Metz LM, Todoruk TR, et al. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler. 2007;13:517–26. https://doi.org/10.1177/1352458506070319.CrossRefPubMed

166.

Zhang Y, Metz LM, Yong VW, et al. Pilot study of minocycline in relapsing-remitting multiple sclerosis. Can J Neurol Sci. 2008;35:185–91. https://doi.org/10.1017/s0317167100008611.CrossRefPubMed

167.

Metz LM, Li D, Traboulsee A, et al. Glatiramer acetate in combination with minocycline in patients with relapsing–remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult Scler. 2009;15:1183–94. https://doi.org/10.1177/1352458509106779.CrossRefPubMed

168.

Sorensen PS, Sellebjerg F, Lycke J, et al. Minocycline added to subcutaneous interferon beta-1a in multiple sclerosis: randomized RECYCLINE study. Eur J Neurol. 2016;23:861–70. https://doi.org/10.1111/ene.12953.CrossRefPubMed

169.

Metz LM, Li DKB, Traboulsee AL, et al. Trial of minocycline in a clinically isolated syndrome of multiple sclerosis. N Engl J Med. 2017;376:2122–33. https://doi.org/10.1056/NEJMoa1608889.CrossRefPubMed

170.

Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413–28. https://doi.org/10.1016/s0163-7258(99)00045-5.CrossRefPubMed

171.

Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30. https://doi.org/10.1016/s0140-6736(02)11600-x.CrossRefPubMed

172.

Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621–7. https://doi.org/10.1056/NEJM199509073331003.CrossRefPubMed

173.

Greenwood J, Walters CE, Pryce G, et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 2003;17:905–7. https://doi.org/10.1096/fj.02-1014fje.CrossRefPubMed

174.

Stuve O, Prod’homme T, Slavin A, et al. Statins and their potential targets in multiple sclerosis therapy. Expert Opin Ther Targets. 2003;7:613–22. https://doi.org/10.1517/14728222.7.5.613.CrossRefPubMed

175.

Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6:358–70. https://doi.org/10.1038/nri1839.CrossRefPubMed

176.

Bosel J, Gandor F, Harms C, et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem. 2005;92:1386–98. https://doi.org/10.1111/j.1471-4159.2004.02980.x.CrossRefPubMed

177.

Paintlia AS, Paintlia MK, Singh AK, Singh I. Modulation of Rho-Rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPAR-alpha-dependent mechanism. Glia. 2013;61:1500–17. https://doi.org/10.1002/glia.22537.CrossRefPubMedPubMedCentral

178.

Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest. 1997;100:2671–9. https://doi.org/10.1172/JCI119812.CrossRefPubMedPubMedCentral

179.

Colombo E, Cordiglieri C, Melli G, et al. Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration. J Exp Med. 2012;209:521–35. https://doi.org/10.1084/jem.20110698.CrossRefPubMedPubMedCentral

180.

Brorson JR, Schumacker PT, Zhang H. Nitric oxide acutely inhibits neuronal energy production. The Committees on Neurobiology and Cell Physiology. J Neurosci. 1999;19:147–58.CrossRef

181.

Mancini A, Tantucci M, Mazzocchetti P, et al. Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis. Neurobiol Dis. 2018;113:97–108. https://doi.org/10.1016/j.nbd.2018.01.002.CrossRefPubMed

182.

Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004;363:1607–8. https://doi.org/10.1016/S0140-6736(04)16205-3.CrossRefPubMed

183.

Sena A, Pedrosa R, Graca Morais M. Therapeutic potential of lovastatin in multiple sclerosis. J Neurol. 2003;250:754–5. https://doi.org/10.1007/s00415-003-1070-8.CrossRefPubMed

184.

Paul F, Waiczies S, Wuerfel J, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One. 2008;3:e1928. https://doi.org/10.1371/journal.pone.0001928.CrossRefPubMedPubMedCentral

185.

Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008;71:1390–5. https://doi.org/10.1212/01.wnl.0000319698.40024.1c.CrossRefPubMed

186.

Sorensen PS, Lycke J, Eralinna JP, et al. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011;10:691–701. https://doi.org/10.1016/S1474-4422(11)70144-2.CrossRefPubMed

187.

Lanzillo R, Orefice G, Quarantelli M, et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler. 2010;16:450–4. https://doi.org/10.1177/1352458509358909.CrossRefPubMed

188.

Lanzillo R, Quarantelli M, Pozzilli C, et al. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon beta1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). Mult Scler. 2016;22:1163–73. https://doi.org/10.1177/1352458515611222.CrossRefPubMed

189.

Kamm CP, El-Koussy M, Humpert S, et al. Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. J Neurol. 2012;259:2401–13. https://doi.org/10.1007/s00415-012-6513-7.CrossRefPubMedPubMedCentral

190.

Rudick RA, Pace A, Rani MR, et al. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology. 2009;72:1989–93. https://doi.org/10.1212/WNL.0b013e3181a92b96.CrossRefPubMedPubMedCentral

191.

Pihl-Jensen G, Tsakiri A, Frederiksen JL. Statin treatment in multiple sclerosis: a systematic review and meta-analysis. CNS Drugs. 2015;29:277–91. https://doi.org/10.1007/s40263-015-0239-x.CrossRefPubMed

192.

Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014;383:2213–21. https://doi.org/10.1016/S0140-6736(13)62242-4.CrossRefPubMed

193.

Chan D, Binks S, Nicholas JM, et al. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol. 2017;16:591–600. https://doi.org/10.1016/S1474-4422(17)30113-8.CrossRefPubMedPubMedCentral

194.

Shrager P, Custer AW, Kazarinova K, Rasband MN, Mattson D. Nerve conduction block by nitric oxide that is mediated by the axonal environment. J Neurophysiol. 1998;79:529–36. https://doi.org/10.1152/jn.1998.79.2.529.CrossRefPubMed

195.

Redford EJ, Kapoor R, Smith KJ. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain. 1997;120(Pt 12):2149–57. https://doi.org/10.1093/brain/120.12.2149.CrossRefPubMed

196.

Chen C, Schofield GG. Nitric oxide modulates Ca²⁺ channel currents in rat sympathetic neurons. Eur J Pharmacol. 1993;243:83–6. https://doi.org/10.1016/0014-2999(93)90171-d.CrossRefPubMed

197.

Chen C, Schofield GG. Nitric oxide donors enhanced Ca²⁺ currents and blocked noradrenaline-induced Ca²⁺ current inhibition in rat sympathetic neurons. J Physiol. 1995;482(Pt 3):521–31. https://doi.org/10.1113/jphysiol.1995.sp020537.CrossRefPubMedPubMedCentral

198.

Craner MJ, Newcombe J, Black JA, Hartle C, Cuzner ML, Waxman SG. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na⁺/Ca²⁺ exchanger. Proc Natl Acad Sci USA. 2004;101:8168–73. https://doi.org/10.1073/pnas.0402765101.CrossRefPubMedPubMedCentral

199.

Petracca M, Vancea RO, Fleysher L, Jonkman LE, Oesingmann N, Inglese M. Brain intra- and extracellular sodium concentration in multiple sclerosis: a 7 T MRI study. Brain. 2016;139:795–806. https://doi.org/10.1093/brain/awv386.CrossRefPubMed

200.

Albuck AL, Sakamuri S, Sperling JA, et al. Peroxynitrite decomposition catalyst enhances respiratory function in isolated brain mitochondria. Am J Physiol Heart Circ Physiol. 2021;320:H630–41. https://doi.org/10.1152/ajpheart.00389.2020.CrossRefPubMed

201.

Anderson G, Rodriguez M, Reiter RJ. Multiple sclerosis: melatonin, orexin, and ceramide interact with platelet activation coagulation factors and gut-microbiome-derived butyrate in the circadian dysregulation of mitochondria in glia and immune cells. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20215500.CrossRefPubMedPubMedCentral

202.

Kapoor R. Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine. J Neurol Sci. 2008;274:54–6. https://doi.org/10.1016/j.jns.2008.03.019.CrossRefPubMed

203.

Cherchi F, Bulli I, Venturini M, Pugliese AM, Coppi E. Ion channels as new attractive targets to improve re-myelination processes in the brain. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22147277.CrossRefPubMedPubMedCentral

204.

Criscuolo C, Cianflone A, Lanzillo R, et al. Glatiramer Acetate modulates ion channels expression and calcium homeostasis in B cell of patients with relapsing-remitting multiple sclerosis. Sci Rep. 2019;9:4208. https://doi.org/10.1038/s41598-018-38152-8.CrossRefPubMedPubMedCentral

205.

Karadottir R, Hamilton NB, Bakiri Y, Attwell D. Spiking and nonspiking classes of oligodendrocyte precursor glia in CNS white matter. Nat Neurosci. 2008;11:450–6. https://doi.org/10.1038/nn2060.CrossRefPubMedPubMedCentral

206.

Black JA, Waxman SG, Smith KJ. Remyelination of dorsal column axons by endogenous Schwann cells restores the normal pattern of Nav1.6 and Kv1.2 at nodes of Ranvier. Brain. 2006;129:1319–29. https://doi.org/10.1093/brain/awl057.CrossRefPubMed

207.

Alrashdi B, Dawod B, Schampel A, et al. Nav1.6 promotes inflammation and neuronal degeneration in a mouse model of multiple sclerosis. J Neuroinflamm. 2019;16:215. https://doi.org/10.1186/s12974-019-1622-1.CrossRef

208.

Shields SD, Butt RP, Dib-Hajj SD, Waxman SG. Oral administration of PF-01247324, a subtype-selective Nav1.8 blocker, reverses cerebellar deficits in a mouse model of multiple sclerosis. PLoS One. 2015;10:e0119067. https://doi.org/10.1371/journal.pone.0119067.CrossRefPubMedPubMedCentral

209.

Larson VA, Zhang Y, Bergles DE. Electrophysiological properties of NG2(+) cells: matching physiological studies with gene expression profiles. Brain Res. 2016;1638:138–60. https://doi.org/10.1016/j.brainres.2015.09.010.CrossRefPubMed

210.

Santiago Gonzalez DA, Cheli VT, Zamora NN, et al. Conditional deletion of the L-type calcium channel Cav1.2 in NG2-positive cells impairs remyelination in mice. J Neurosci. 2017;37:10038–51. https://doi.org/10.1523/JNEUROSCI.1787-17.2017.CrossRefPubMedPubMedCentral

211.

Cheli VT, Santiago Gonzalez DA, et al. Conditional deletion of the l-type calcium channel Cav1.2 in oligodendrocyte progenitor cells affects postnatal myelination in mice. J Neurosci. 2016;36:10853–69. https://doi.org/10.1523/JNEUROSCI.1770-16.2016.CrossRefPubMedPubMedCentral

212.

Zamora NN, Cheli VT, Santiago Gonzalez DA, Wan R, Paez PM. Deletion of voltage-gated calcium channels in astrocytes during demyelination reduces brain inflammation and promotes myelin regeneration in mice. J Neurosci. 2020;40:3332–47. https://doi.org/10.1523/JNEUROSCI.1644-19.2020.CrossRefPubMedPubMedCentral

213.

Schampel A, Volovitch O, Koeniger T, et al. Nimodipine fosters remyelination in a mouse model of multiple sclerosis and induces microglia-specific apoptosis. Proc Natl Acad Sci U S A. 2017;114:E3295–304. https://doi.org/10.1073/pnas.1620052114.CrossRefPubMedPubMedCentral

214.

Larson VA, Mironova Y, Vanderpool KG, et al. Oligodendrocytes control potassium accumulation in white matter and seizure susceptibility. Elife. 2018. https://doi.org/10.7554/eLife.34829.CrossRefPubMedPubMedCentral

215.

Schirmer L, Mobius W, Zhao C, et al. Oligodendrocyte-encoded Kir4.1 function is required for axonal integrity. Elife. 2018. https://doi.org/10.7554/eLife.36428.CrossRefPubMedPubMedCentral

216.

Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med. 2012;367:115–23. https://doi.org/10.1056/NEJMoa1110740.CrossRefPubMedPubMedCentral

217.

Jukkola PI, Lovett-Racke AE, Zamvil SS, Gu C. K+ channel alterations in the progression of experimental autoimmune encephalomyelitis. Neurobiol Dis. 2012;47:280–93. https://doi.org/10.1016/j.nbd.2012.04.012.CrossRefPubMedPubMedCentral

218.

Raftopoulos R, Hickman SJ, Toosy A, et al. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:259–69. https://doi.org/10.1016/S1474-4422(16)00004-1.CrossRefPubMed

219.

Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 2010;9:681–8. https://doi.org/10.1016/S1474-4422(10)70131-9.CrossRefPubMed

220.

Iorio R, Capone F, Plantone D, Batocchi AP. Paroxysmal ataxia and dysarthria in multiple sclerosis. J Clin Neurosci. 2014;21:174–5. https://doi.org/10.1016/j.jocn.2013.01.031.CrossRefPubMed

221.

Li Y, Zeng C, Luo T. Paroxysmal dysarthria and ataxia in multiple sclerosis and corresponding magnetic resonance imaging findings. J Neurol. 2011;258:273–6. https://doi.org/10.1007/s00415-010-5748-4.CrossRefPubMed

222.

Myhre M, Jacobsen HB, Andersson S, Stubhaug A. Cognitive effects of perioperative pregabalin: secondary exploratory analysis of a randomized placebo-controlled study. Anesthesiology. 2019;130:63–71. https://doi.org/10.1097/ALN.0000000000002473.CrossRefPubMed

223.

Albrecht P, Bjorna IK, Brassat D, et al. Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. Ther Adv Neurol Disord. 2018;11:1756286418803248. https://doi.org/10.1177/1756286418803248.CrossRefPubMedPubMedCentral

224.

Hobart J, Ziemssen T, Feys P, et al. Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, pase III ENHANCE trial of prolonged-release fampridine. CNS Drugs. 2019;33:61–79. https://doi.org/10.1007/s40263-018-0586-5.CrossRefPubMed

225.

Schofield J, Derdau V, Atzrodt J, et al. Effect of deuteration on metabolism and clearance of nerispirdine (HP184) and AVE5638. Bioorg Med Chem. 2015;23:3831–42. https://doi.org/10.1016/j.bmc.2015.03.065.CrossRefPubMed

226.

De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology. 2003;60:1157–62. https://doi.org/10.1212/01.wnl.0000055926.69643.03.CrossRefPubMed

227.

Roosendaal SD, Bendfeldt K, Vrenken H, et al. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler. 2011;17:1098–106. https://doi.org/10.1177/1352458511404916.CrossRefPubMed

228.

Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001;50:389–400. https://doi.org/10.1002/ana.1123.CrossRefPubMed

229.

Dutta R, Chang A, Doud MK, et al. Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol. 2011;69:445–54. https://doi.org/10.1002/ana.22337.CrossRefPubMedPubMedCentral

230.

Hammond JW, Bellizzi MJ, Ware C, et al. Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis. Brain Behav Immun. 2020;87:739–50. https://doi.org/10.1016/j.bbi.2020.03.004.CrossRefPubMedPubMedCentral

231.

Yang G, Parkhurst CN, Hayes S, Gan WB. Peripheral elevation of TNF-alpha leads to early synaptic abnormalities in the mouse somatosensory cortex in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2013;110:10306–11. https://doi.org/10.1073/pnas.1222895110.CrossRefPubMedPubMedCentral

232.

van Horssen J, Witte ME, Ciccarelli O. The role of mitochondria in axonal degeneration and tissue repair in MS. Mult Scler. 2012;18:1058–67. https://doi.org/10.1177/1352458512452924.CrossRefPubMed

233.

Bellingacci L, Mancini A, Gaetani L, Tozzi A, Parnetti L, Di Filippo M. Synaptic dysfunction in multiple sclerosis: a red thread from inflammation to network disconnection. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22189753.CrossRefPubMedPubMedCentral

234.

Kerschensteiner M, Bareyre FM, Buddeberg BS, et al. Remodeling of axonal connections contributes to recovery in an animal model of multiple sclerosis. J Exp Med. 2004;200:1027–38. https://doi.org/10.1084/jem.20040452.CrossRefPubMedPubMedCentral

235.

Sarchielli P, Greco L, Floridi A, Floridi A, Gallai V. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch Neurol. 2003;60:1082–8. https://doi.org/10.1001/archneur.60.8.1082.CrossRefPubMed

236.

Pampliega O, Domercq M, Soria FN, Villoslada P, Rodriguez-Antiguedad A, Matute C. Increased expression of cystine/glutamate antiporter in multiple sclerosis. J Neuroinflamm. 2011;8:63. https://doi.org/10.1186/1742-2094-8-63.CrossRef

237.

Pacheco R, Oliva H, Martinez-Navio JM, et al. Glutamate released by dendritic cells as a novel modulator of T cell activation. J Immunol. 2006;177:6695–704. https://doi.org/10.4049/jimmunol.177.10.6695.CrossRefPubMed

238.

Evonuk KS, Baker BJ, Doyle RE, et al. Inhibition of system Xc(-) transporter attenuates autoimmune inflammatory demyelination. J Immunol. 2015;195:450–63. https://doi.org/10.4049/jimmunol.1401108.CrossRefPubMed

239.

Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol. 2001;50:169–80. https://doi.org/10.1002/ana.1077.CrossRefPubMed

240.

Joshi DC, Tewari BP, Singh M, Joshi PG, Joshi NB. AMPA receptor activation causes preferential mitochondrial Ca(2)(+) load and oxidative stress in motor neurons. Brain Res. 2015;1616:1–9. https://doi.org/10.1016/j.brainres.2015.04.042.CrossRefPubMed

241.

Docagne F, Muneton V, Clemente D, et al. Excitotoxicity in a chronic model of multiple sclerosis: neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Mol Cell Neurosci. 2007;34:551–61. https://doi.org/10.1016/j.mcn.2006.12.005.CrossRefPubMed

242.

Zhai D, Lee FH, D’Souza C, et al. Blocking GluR2-GAPDH ameliorates experimental autoimmune encephalomyelitis. Ann Clin Transl Neurol. 2015;2:388–400. https://doi.org/10.1002/acn3.182.CrossRefPubMedPubMedCentral

243.

Zhai D, Li S, Wang M, Chin K, Liu F. Disruption of the GluR2/GAPDH complex protects against ischemia-induced neuronal damage. Neurobiol Dis. 2013;54:392–403. https://doi.org/10.1016/j.nbd.2013.01.013.CrossRefPubMed

244.

Wallstrom E, Diener P, Ljungdahl A, Khademi M, Nilsson CG, Olsson T. Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J Neurol Sci. 1996;137:89–96. https://doi.org/10.1016/0022-510x(95)00339-4.CrossRefPubMed

245.

Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11:682–96. https://doi.org/10.1038/nrn2911.CrossRefPubMedPubMedCentral

246.

Sulkowski G, Dabrowska-Bouta B, Chalimoniuk M, Struzynska L. Effects of antagonists of glutamate receptors on pro-inflammatory cytokines in the brain cortex of rats subjected to experimental autoimmune encephalomyelitis. J Neuroimmunol. 2013;261:67–76. https://doi.org/10.1016/j.jneuroim.2013.05.006.CrossRefPubMed

247.

Turalde CWR, Espiritu AI, Anlacan VMM. Memantine for multiple sclerosis: a systematic review and meta-analysis of randomized trials. Front Neurol. 2020;11:574748. https://doi.org/10.3389/fneur.2020.574748.CrossRefPubMed

248.

PeyroSaintPaul L, Creveuil C, Heinzlef O, et al. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: a randomized, placebo-controlled study. J Neurol Sci. 2016;363:69–76. https://doi.org/10.1016/j.jns.2016.02.012.CrossRef

249.

Mehta LR, McDermott MP, Goodman AD, Schwid SR. A randomized trial of memantine as treatment for spasticity in multiple sclerosis. Mult Scler. 2010;16:248–51. https://doi.org/10.1177/1352458509355462.CrossRefPubMed

250.

Lovera JF, Frohman E, Brown TR, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16:715–23. https://doi.org/10.1177/1352458510367662.CrossRefPubMed

251.

Falsafi Z, Tafakhori A, Agah E, et al. Safety and efficacy of memantine for multiple sclerosis-related fatigue: a pilot randomized, double-blind placebo-controlled trial. J Neurol Sci. 2020;414:116844. https://doi.org/10.1016/j.jns.2020.116844.CrossRefPubMed

252.

Cohen JA, Cameron MH, Goldman MD, et al. A phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. Mult Scler. 2021. https://doi.org/10.1177/13524585211035333.CrossRefPubMedPubMedCentral

253.

Cohen JA, Hunter SF, Brown TR, et al. Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: a randomized, placebo-controlled, phase 2 trial. Mult Scler. 2019;25:601–9. https://doi.org/10.1177/1352458518754716.CrossRefPubMed

254.

Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 1995;45:1956–61. https://doi.org/10.1212/wnl.45.11.1956.CrossRefPubMed

255.

Nourbakhsh B, Revirajan N, Morris B, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol. 2021;20:38–48. https://doi.org/10.1016/S1474-4422(20)30354-9.CrossRefPubMed

256.

Saligan LN, Luckenbaugh DA, Slonena EE, Machado-Vieira R, Zarate CA Jr. An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. J Affect Disord. 2016;194:115–9. https://doi.org/10.1016/j.jad.2016.01.009.CrossRefPubMedPubMedCentral

257.

Fitzgerald KC, Morris B, Soroosh A, et al. Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue. Mult Scler. 2021;27:942–53. https://doi.org/10.1177/1352458520936226.CrossRefPubMed

258.

Gilgun-Sherki Y, Panet H, Melamed E, Offen D. Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res. 2003;989:196–204. https://doi.org/10.1016/s0006-8993(03)03343-2.CrossRefPubMed

259.

Killestein J, Kalkers NF, Polman CH. Glutamate inhibition in MS: the neuroprotective properties of riluzole. J Neurol Sci. 2005;233:113–5. https://doi.org/10.1016/j.jns.2005.03.011.CrossRefPubMed

260.

Waubant E, Maghzi AH, Revirajan N, et al. A randomized controlled phase II trial of riluzole in early multiple sclerosis. Ann Clin Transl Neurol. 2014;1:340–7. https://doi.org/10.1002/acn3.60.CrossRefPubMedPubMedCentral

261.

De Angelis F, Connick P, Parker RA, et al. Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Efficacy Mech Eval. 2020;7(3). https://doi.org/10.3310/eme07030.

262.

Chataway J, De Angelis F, Connick P, et al. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurol. 2020;19:214–25. https://doi.org/10.1016/S1474-4422(19)30485-5.CrossRefPubMedPubMedCentral

263.

Jablonski MR, Markandaiah SS, Jacob D, et al. Inhibiting drug efflux transporters improves efficacy of ALS therapeutics. Ann Clin Transl Neurol. 2014;1:996–1005. https://doi.org/10.1002/acn3.141.CrossRefPubMedPubMedCentral

264.

Diotel N, Charlier TD, Lefebvre d’Hellencourt C, et al. Steroid transport, local synthesis, and signaling within the brain: roles in neurogenesis, neuroprotection, and sexual behaviors. Front Neurosci. 2018;12:84. https://doi.org/10.3389/fnins.2018.00084.CrossRefPubMedPubMedCentral

265.

Parimisetty A, Dorsemans AC, Awada R, Ravanan P, Diotel N, Lefebvre d’Hellencourt C. Secret talk between adipose tissue and central nervous system via secreted factors-an emerging frontier in the neurodegenerative research. J Neuroinflamm. 2016;13:67. https://doi.org/10.1186/s12974-016-0530-x.CrossRef

266.

Xiao H, Deng M, Yang B, Hu Z, Tang J. Pretreatment with 17beta-estradiol attenuates cerebral ischemia-induced blood-brain barrier disruption in aged rats: involvement of antioxidant signaling. Neuroendocrinology. 2018;106:20–9. https://doi.org/10.1159/000455866.CrossRefPubMed

267.

Maggioli E, McArthur S, Mauro C, et al. Estrogen protects the blood-brain barrier from inflammation-induced disruption and increased lymphocyte trafficking. Brain Behav Immun. 2016;51:212–22. https://doi.org/10.1016/j.bbi.2015.08.020.CrossRefPubMed

268.

Bake S, Sohrabji F. 17beta-estradiol differentially regulates blood-brain barrier permeability in young and aging female rats. Endocrinology. 2004;145:5471–5. https://doi.org/10.1210/en.2004-0984.CrossRefPubMed

269.

Atallah A, Mhaouty-Kodja S, Grange-Messent V. Chronic depletion of gonadal testosterone leads to blood-brain barrier dysfunction and inflammation in male mice. J Cereb Blood Flow Metab. 2017;37:3161–75. https://doi.org/10.1177/0271678X16683961.CrossRefPubMed

270.

Si D, Li J, Liu J, et al. Progesterone protects blood-brain barrier function and improves neurological outcome following traumatic brain injury in rats. Exp Ther Med. 2014;8:1010–4. https://doi.org/10.3892/etm.2014.1840.CrossRefPubMedPubMedCentral

271.

Ishrat T, Sayeed I, Atif F, Hua F, Stein DG. Progesterone and allopregnanolone attenuate blood-brain barrier dysfunction following permanent focal ischemia by regulating the expression of matrix metalloproteinases. Exp Neurol. 2010;226:183–90. https://doi.org/10.1016/j.expneurol.2010.08.023.CrossRefPubMedPubMedCentral

272.

Ysrraelit MC, Correale J. Impact of sex hormones on immune function and multiple sclerosis development. Immunology. 2019;156:9–22. https://doi.org/10.1111/imm.13004.CrossRefPubMed

273.

Yang L, Zhou R, Tong Y, et al. Neuroprotection by dihydrotestosterone in LPS-induced neuroinflammation. Neurobiol Dis. 2020;140: 104814. https://doi.org/10.1016/j.nbd.2020.104814.CrossRefPubMed

274.

Taleb O, Bouzobra F, Tekin-Pala H, Meyer L, Mensah-Nyagan AG, Patte-Mensah C. Behavioral and electromyographic assessment of oxaliplatin-induced motor dysfunctions: evidence for a therapeutic effect of allopregnanolone. Behav Brain Res. 2017;320:440–9. https://doi.org/10.1016/j.bbr.2016.10.040.CrossRefPubMed

275.

Patte-Mensah C, Meyer L, Taleb O, Mensah-Nyagan AG. Potential role of allopregnanolone for a safe and effective therapy of neuropathic pain. Prog Neurobiol. 2014;113:70–8. https://doi.org/10.1016/j.pneurobio.2013.07.004.CrossRefPubMed

276.

Meyer L, Taleb O, Patte-Mensah C, Mensah-Nyagan AG. Neurosteroids and neuropathic pain management: basic evidence and therapeutic perspectives. Front Neuroendocrinol. 2019;55:100795. https://doi.org/10.1016/j.yfrne.2019.100795.CrossRefPubMed

277.

Mensah-Nyagan AG, Meyer L, Schaeffer V, Kibaly C, Patte-Mensah C. Evidence for a key role of steroids in the modulation of pain. Psychoneuroendocrinology. 2009;34(Suppl 1):S169-177. https://doi.org/10.1016/j.psyneuen.2009.06.004.CrossRefPubMed

278.

Gonzalez SL, Meyer L, Raggio MC, et al. Allopregnanolone and progesterone in experimental neuropathic pain: former and new insights with a translational perspective. Cell Mol Neurobiol. 2019;39:523–37. https://doi.org/10.1007/s10571-018-0618-1.CrossRefPubMed

279.

Charlier TD, Cornil CA, Patte-Mensah C, Meyer L, Mensah-Nyagan AG, Balthazart J. Local modulation of steroid action: rapid control of enzymatic activity. Front Neurosci. 2015;9:83. https://doi.org/10.3389/fnins.2015.00083.CrossRefPubMedPubMedCentral

280.

Trenova AG, Slavov GS, Manova MG, Kostadinova II, Vasileva TV. Female sex hormones and cytokine secretion in women with multiple sclerosis. Neurol Res. 2013;35:95–9. https://doi.org/10.1179/1743132812Y.0000000120.CrossRefPubMed

281.

Avila M, Bansal A, Culberson J, Peiris AN. The role of sex hormones in multiple sclerosis. Eur Neurol. 2018;80:93–9. https://doi.org/10.1159/000494262.CrossRefPubMed

282.

Maglione A, Rolla S, Mercanti SF, Cutrupi S, Clerico M. The adaptive immune system in multiple sclerosis: an estrogen-mediated point of view. Cells. 2019. https://doi.org/10.3390/cells8101280.CrossRefPubMedPubMedCentral

283.

Crabtree-Hartman E. Sex differences in multiple sclerosis. Continuum (Minneap Minn). 2010;16:193–210. https://doi.org/10.1212/01.CON.0000389942.81981.72.CrossRef

284.

De Nicola AF, Gonzalez Deniselle MC, Garay L, et al. Progesterone protective effects in neurodegeneration and neuroinflammation. J Neuroendocrinol. 2013;25:1095–103. https://doi.org/10.1111/jne.12043.CrossRefPubMed

285.

Garay L, Gonzalez Deniselle MC, Lima A, Roig P, De Nicola AF. Effects of progesterone in the spinal cord of a mouse model of multiple sclerosis. J Steroid Biochem Mol Biol. 2007;107:228–37. https://doi.org/10.1016/j.jsbmb.2007.03.040.CrossRefPubMed

286.

Noorbakhsh F, Ellestad KK, Maingat F, et al. Impaired neurosteroid synthesis in multiple sclerosis. Brain. 2011;134:2703–21. https://doi.org/10.1093/brain/awr200.CrossRefPubMedPubMedCentral

287.

Noorbakhsh F, Baker GB, Power C. Allopregnanolone and neuroinflammation: a focus on multiple sclerosis. Front Cell Neurosci. 2014;8:134. https://doi.org/10.3389/fncel.2014.00134.CrossRefPubMedPubMedCentral

288.

Leva G, Klein C, Benyounes J, et al. The translocator protein ligand XBD173 improves clinical symptoms and neuropathological markers in the SJL/J mouse model of multiple sclerosis. Biochim Biophys Acta Mol Basis Dis. 2017;1863:3016–27. https://doi.org/10.1016/j.bbadis.2017.09.007.CrossRefPubMed

289.

Jolivel V, Brun S, Biname F, et al. Microglial cell morphology and phagocytic activity are critically regulated by the neurosteroid allopregnanolone: a possible role in neuroprotection. Cells. 2021. https://doi.org/10.3390/cells10030698.CrossRefPubMedPubMedCentral

290.

Collongues N, Patte-Mensah C, De Seze J, Mensah-Nyagan AG, Derfuss T. Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics. Expert Rev Neurother. 2018;18:515–22. https://doi.org/10.1080/14737175.2018.1481390.CrossRefPubMed

291.

Chitnis T. The role of testosterone in MS risk and course. Mult Scler. 2018;24:36–41. https://doi.org/10.1177/1352458517737395.CrossRefPubMed

292.

Bove R, Musallam A, Healy BC, et al. Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler. 2014;20:1584–92. https://doi.org/10.1177/1352458514527864.CrossRefPubMedPubMedCentral

293.

Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol. 2002;52:421–8. https://doi.org/10.1002/ana.10301.CrossRefPubMed

294.

Vukusic S, Ionescu I, El-Etr M, et al. The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART’MUS) trial: rationale, objectives and state of advancement. J Neurol Sci. 2009;286:114–8. https://doi.org/10.1016/j.jns.2009.08.056.CrossRefPubMed

295.

Vukusic S, Ionescu I, Cornu C, et al. Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: the POPARTMUS study. Mult Scler. 2021;27:1458–63. https://doi.org/10.1177/1352458520978218.CrossRefPubMed

296.

Voskuhl RR, Wang H, Wu TC, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:35–46. https://doi.org/10.1016/S1474-4422(15)00322-1.CrossRefPubMed

297.

Pozzilli C, De Giglio L, Barletta VT, et al. Oral contraceptives combined with interferon beta in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2015;2:e120. https://doi.org/10.1212/NXI.0000000000000120.CrossRefPubMedPubMedCentral

298.

Sicotte NL, Giesser BS, Tandon V, et al. Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol. 2007;64:683–8. https://doi.org/10.1001/archneur.64.5.683.CrossRefPubMed

299.

Gold SM, Chalifoux S, Giesser BS, Voskuhl RR. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J Neuroinflamm. 2008;5:32. https://doi.org/10.1186/1742-2094-5-32.CrossRef

300.

Kurth F, Luders E, Sicotte NL, et al. Neuroprotective effects of testosterone treatment in men with multiple sclerosis. Neuroimage Clin. 2014;4:454–60. https://doi.org/10.1016/j.nicl.2014.03.001.CrossRefPubMedPubMedCentral

301.

Metzger-Peter K, Kremer LD, Edan G, et al. The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial. Trials. 2020;21:591. https://doi.org/10.1186/s13063-020-04517-6.CrossRefPubMedPubMedCentral

302.

Clemente D, Ortega MC, Melero-Jerez C, de Castro F. The effect of glia-glia interactions on oligodendrocyte precursor cell biology during development and in demyelinating diseases. Front Cell Neurosci. 2013;7:268. https://doi.org/10.3389/fncel.2013.00268.CrossRefPubMedPubMedCentral

303.

Harirchian MH, Tekieh AH, Modabbernia A, et al. Serum and CSF PDGF-AA and FGF-2 in relapsing-remitting multiple sclerosis: a case-control study. Eur J Neurol. 2012;19:241–7. https://doi.org/10.1111/j.1468-1331.2011.03476.x.CrossRefPubMed

304.

Perkins LA, Cain LD. Basic fibroblast growth factor (bFGF) increases the survival of embryonic and postnatal basal forebrain cholinergic neurons in primary culture. Int J Dev Neurosci. 1995;13:51–61. https://doi.org/10.1016/0736-5748(94)00066-c.CrossRefPubMed

305.

Dehghan S, Javan M, Pourabdolhossein F, Mirnajafi-Zadeh J, Baharvand H. Basic fibroblast growth factor potentiates myelin repair following induction of experimental demyelination in adult mouse optic chiasm and nerves. J Mol Neurosci. 2012;48:77–85. https://doi.org/10.1007/s12031-012-9777-6.CrossRefPubMed

306.

Azin M, Mirnajafi-Zadeh J, Javan M. Fibroblast growth factor-2 enhanced the recruitment of progenitor cells and myelin repair in experimental demyelination of rat hippocampal formations. Cell J. 2015;17:540–456. https://doi.org/10.22074/cellj.2015.14.CrossRefPubMedPubMedCentral

307.

Rottlaender A, Villwock H, Addicks K, Kuerten S. Neuroprotective role of fibroblast growth factor-2 in experimental autoimmune encephalomyelitis. Immunology. 2011;133:370–8. https://doi.org/10.1111/j.1365-2567.2011.03450.x.CrossRefPubMedPubMedCentral

308.

Zhou YX, Pannu R, Le TQ, Armstrong RC. Fibroblast growth factor 1 (FGFR1) modulation regulates repair capacity of oligodendrocyte progenitor cells following chronic demyelination. Neurobiol Dis. 2012;45:196–205. https://doi.org/10.1016/j.nbd.2011.08.004.CrossRefPubMed

309.

Furusho M, Roulois AJ, Franklin RJ, Bansal R. Fibroblast growth factor signaling in oligodendrocyte-lineage cells facilitates recovery of chronically demyelinated lesions but is redundant in acute lesions. Glia. 2015;63:1714–28. https://doi.org/10.1002/glia.22838.CrossRefPubMedPubMedCentral

310.

Rajendran R, Bottiger G, Stadelmann C, Karnati S, Berghoff M. FGF/FGFR pathways in multiple sclerosis and in its disease models. Cells. 2021. https://doi.org/10.3390/cells10040884.CrossRefPubMedPubMedCentral

311.

Yemisci M, Caban S, Gursoy-Ozdemir Y, et al. Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection. J Cereb Blood Flow Metab. 2015;35:469–75. https://doi.org/10.1038/jcbfm.2014.220.CrossRefPubMed

312.

Stadelmann C, Kerschensteiner M, Misgeld T, Bruck W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain. 2002;125:75–85. https://doi.org/10.1093/brain/awf015.CrossRefPubMed

313.

Caggiula M, Batocchi AP, Frisullo G, et al. Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scand J Immunol. 2005;62:176–82. https://doi.org/10.1111/j.1365-3083.2005.01649.x.CrossRefPubMed

314.

VonDran MW, Singh H, Honeywell JZ, Dreyfus CF. Levels of BDNF impact oligodendrocyte lineage cells following a cuprizone lesion. J Neurosci. 2011;31:14182–90. https://doi.org/10.1523/JNEUROSCI.6595-10.2011.CrossRefPubMedPubMedCentral

315.

Makar TK, Bever CT, Singh IS, et al. Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J Neuroimmunol. 2009;210:40–51. https://doi.org/10.1016/j.jneuroim.2009.02.017.CrossRefPubMed

316.

Wu Y, Luo X, Liu X, et al. Intraperitoneal administration of a novel TAT-BDNF peptide ameliorates cognitive impairments via modulating multiple pathways in two Alzheimer’s rodent models. Sci Rep. 2015;5:15032. https://doi.org/10.1038/srep15032.CrossRefPubMedPubMedCentral

317.

Massa SM, Yang T, Xie Y, et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest. 2010;120:1774–85. https://doi.org/10.1172/JCI41356.CrossRefPubMedPubMedCentral

318.

Wilczak N, Ramsaransing GS, Mostert J, Chesik D, De Keyser J. Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis. Mult Scler. 2005;11:13–5. https://doi.org/10.1191/1352458505ms1123oa.CrossRefPubMed

319.

Wilczak N, De Keyser J. Insulin-like growth factor-I receptors in normal appearing white matter and chronic plaques in multiple sclerosis. Brain Res. 1997;772:243–6. https://doi.org/10.1016/s0006-8993(97)00940-2.CrossRefPubMed

320.

Pirttila T, Vanhatalo S, Turpeinen U, Riikonen R. Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS. Acta Neurol Scand. 2004;109:337–41. https://doi.org/10.1111/j.1600-0404.2004.00223.x.CrossRefPubMed

321.

Liu X, Yao DL, Bondy CA, et al. Astrocytes express insulin-like growth factor-I (IGF-I) and its binding protein, IGFBP-2, during demyelination induced by experimental autoimmune encephalomyelitis. Mol Cell Neurosci. 1994;5:418–30. https://doi.org/10.1006/mcne.1994.1052.CrossRefPubMed

322.

Gudi V, Skuljec J, Yildiz O, et al. Spatial and temporal profiles of growth factor expression during CNS demyelination reveal the dynamics of repair priming. PLoS One. 2011;6:e22623. https://doi.org/10.1371/journal.pone.0022623.CrossRefPubMedPubMedCentral

323.

Mason JL, Xuan S, Dragatsis I, Efstratiadis A, Goldman JE. Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination. J Neurosci. 2003;23:7710–8.CrossRef

324.

Yao DL, Liu X, Hudson LD, Webster HD. Insulin-like growth factor-I given subcutaneously reduces clinical deficits, decreases lesion severity and upregulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis. Life Sci. 1996;58:1301–6. https://doi.org/10.1016/0024-3205(96)00095-1.CrossRefPubMed

325.

Liu X, Linnington C, Webster HD, et al. Insulin-like growth factor-I treatment reduces immune cell responses in acute non-demyelinative experimental autoimmune encephalomyelitis. J Neurosci Res. 1997;47:531–8. https://doi.org/10.1002/(sici)1097-4547(19970301)47:5%3c531::aid-jnr8%3e3.0.co;2-i.CrossRefPubMed

326.

Frank JA, Richert N, Lewis B, et al. A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients. Mult Scler. 2002;8:24–9. https://doi.org/10.1191/1352458502ms768oa.CrossRefPubMed

327.

Sanchis-Gomar F, Garcia-Gimenez JL, Pareja-Galeano H, Romagnoli M, Perez-Quilis C, Lippi G. Erythropoietin and the heart: physiological effects and the therapeutic perspective. Int J Cardiol. 2014;171:116–25. https://doi.org/10.1016/j.ijcard.2013.12.011.CrossRefPubMed

328.

Dang J, Jia R, Tu Y, Xiao S, Ding G. Erythropoietin prevents reactive oxygen species generation and renal tubular cell apoptosis at high glucose level. Biomed Pharmacother. 2010;64:681–5. https://doi.org/10.1016/j.biopha.2010.06.011.CrossRefPubMed

329.

Shingo T, Sorokan ST, Shimazaki T, Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci. 2001;21:9733–43.CrossRef

330.

Sugawa M, Sakurai Y, Ishikawa-Ieda Y, Suzuki H, Asou H. Effects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferation. Neurosci Res. 2002;44:391–403. https://doi.org/10.1016/s0168-0102(02)00161-x.CrossRefPubMed

331.

Cho YK, Kim G, Park S, et al. Erythropoietin promotes oligodendrogenesis and myelin repair following lysolecithin-induced injury in spinal cord slice culture. Biochem Biophys Res Commun. 2012;417:753–9. https://doi.org/10.1016/j.bbrc.2011.12.029.CrossRefPubMed

332.

Agnello D, Bigini P, Villa P, et al. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 2002;952:128–34. https://doi.org/10.1016/s0006-8993(02)03239-0.CrossRefPubMed

333.

Zhang J, Li Y, Cui Y, et al. Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res. 2005;1034:34–9. https://doi.org/10.1016/j.brainres.2004.11.036.CrossRefPubMed

334.

Diem R, Sattler MB, Merkler D, et al. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain. 2005;128:375–85. https://doi.org/10.1093/brain/awh365.CrossRefPubMed

335.

Suhs KW, Hein K, Sattler MB, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol. 2012;72:199–210. https://doi.org/10.1002/ana.23573.CrossRefPubMed

336.

Lagreze WA, Kuchlin S, Ihorst G, et al. Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study. Lancet Neurol. 2021;20:991–1000. https://doi.org/10.1016/S1474-4422(21)00322-7.CrossRefPubMed

337.

Gaindh D, Choi YB, Marchese M, et al. Prolonged beneficial effect of brief erythropoietin peptide JM4 therapy on chronic relapsing EAE. Neurotherapeutics. 2021;18:401–11. https://doi.org/10.1007/s13311-020-00923-5.CrossRefPubMed

338.

Chang R, Al Maghribi A, Vanderpoel V, et al. Brain penetrating bifunctional erythropoietin-transferrin receptor antibody fusion protein for Alzheimer’s disease. Mol Pharm. 2018;15:4963–73. https://doi.org/10.1021/acs.molpharmaceut.8b00594.CrossRefPubMedPubMedCentral

339.

Quinzii CM, Lopez LC, Von-Moltke J, et al. Respiratory chain dysfunction and oxidative stress correlate with severity of primary CoQ10 deficiency. FASEB J. 2008;22:1874–85. https://doi.org/10.1096/fj.07-100149.CrossRefPubMed

340.

Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012;8:647–56. https://doi.org/10.1038/nrneurol.2012.168.CrossRefPubMed

341.

Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol. 2014;10:225–38. https://doi.org/10.1038/nrneurol.2014.37.CrossRefPubMed

342.

Sanoobar M, Eghtesadi S, Azimi A, Khalili M, Jazayeri S, Reza Gohari M. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing-remitting multiple sclerosis. Int J Neurosci. 2013;123:776–82. https://doi.org/10.3109/00207454.2013.801844.CrossRefPubMed

343.

Sanoobar M, Eghtesadi S, Azimi A, et al. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutr Neurosci. 2015;18:169–76. https://doi.org/10.1179/1476830513Y.0000000106.CrossRefPubMed

344.

Sanoobar M, Dehghan P, Khalili M, Azimi A, Seifar F. Coenzyme Q10 as a treatment for fatigue and depression in multiple sclerosis patients: a double blind randomized clinical trial. Nutr Neurosci. 2016;19:138–43. https://doi.org/10.1179/1476830515Y.0000000002.CrossRefPubMed

345.

Moccia M, Capacchione A, Lanzillo R, et al. Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-beta1a-treated multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1756286418819074. https://doi.org/10.1177/1756286418819074.CrossRefPubMedPubMedCentral

346.

Gueven N, Ravishankar P, Eri R, Rybalka E. Idebenone: when an antioxidant is not an antioxidant. Redox Biol. 2021;38: 101812. https://doi.org/10.1016/j.redox.2020.101812.CrossRefPubMed

347.

Fiebiger SM, Bros H, Grobosch T, et al. The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse. J Neuroimmunol. 2013;262:66–71. https://doi.org/10.1016/j.jneuroim.2013.07.002.CrossRefPubMed

348.

Kosa P, Wu T, Phillips J, et al. Idebenone does not inhibit disability progression in primary progressive MS. Mult Scler Relat Disord. 2020;45:102434. https://doi.org/10.1016/j.msard.2020.102434.CrossRefPubMed

349.

Smith RA, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci. 2010;1201:96–103. https://doi.org/10.1111/j.1749-6632.2010.05627.x.CrossRefPubMed

350.

Mao P, Manczak M, Shirendeb UP, Reddy PH. MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Biochim Biophys Acta. 2013;1832:2322–31. https://doi.org/10.1016/j.bbadis.2013.09.005.CrossRefPubMed

351.

Sagheddu C, Melis M, Muntoni AL, Pistis M. Repurposing peroxisome proliferator-activated receptor agonists in neurological and psychiatric disorders. Pharmaceuticals (Basel). 2021. https://doi.org/10.3390/ph14101025.CrossRef

352.

Nolte RT, Wisely GB, Westin S, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 1998;395:137–43. https://doi.org/10.1038/25931.CrossRefPubMed

353.

van Neerven S, Mey J. RAR/RXR and PPAR/RXR signaling in spinal cord injury. PPAR Res. 2007;2007:29275. https://doi.org/10.1155/2007/29275.CrossRefPubMedPubMedCentral

354.

Qi C, Zhu Y, Reddy JK. Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys. 2000;32(Spring):187–204. https://doi.org/10.1385/cbb:32:1-3:187.CrossRefPubMed

355.

Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Curr Diab Rep. 2019;19:151. https://doi.org/10.1007/s11892-019-1270-y.CrossRefPubMedPubMedCentral

356.

Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314:265–77. https://doi.org/10.1001/jama.2015.7996.CrossRefPubMed

357.

Yang XY, Wang LH, Chen T, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem. 2000;275:4541–4. https://doi.org/10.1074/jbc.275.7.4541.CrossRefPubMed

358.

Ricote M, Huang JT, Welch JS, Glass CK. The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function. J Leukoc Biol. 1999;66:733–9. https://doi.org/10.1002/jlb.66.5.733.CrossRefPubMed

359.

Marx N, Mach F, Sauty A, et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol. 2000;164:6503–8. https://doi.org/10.4049/jimmunol.164.12.6503.CrossRefPubMed

360.

Maggi LB Jr, Sadeghi H, Weigand C, Scarim AL, Heitmeier MR, Corbett JA. Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes. 2000;49:346–55. https://doi.org/10.2337/diabetes.49.3.346.CrossRefPubMed

361.

Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82–6. https://doi.org/10.1038/34184.CrossRefPubMed

362.

Harris SG, Phipps RP. The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis. Eur J Immunol. 2001;31:1098–105. https://doi.org/10.1002/1521-4141(200104)31:4%3c1098::aid-immu1098%3e3.0.co;2-i.CrossRefPubMed

363.

Han KH, Chang MK, Boullier A, et al. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. J Clin Invest. 2000;106:793–802. https://doi.org/10.1172/JCI10052.CrossRefPubMedPubMedCentral

364.

Feinstein DL. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther. 2003;5:67–73. https://doi.org/10.1089/152091503763816481.CrossRefPubMed

365.

Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol. 2000;164:1364–71. https://doi.org/10.4049/jimmunol.164.3.1364.CrossRefPubMed

366.

Bernardo A, Levi G, Minghetti L. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-delta12,14-prostaglandin J2 in the regulation of microglial functions. Eur J Neurosci. 2000;12:2215–23. https://doi.org/10.1046/j.1460-9568.2000.00110.x.CrossRefPubMed

367.

Feinstein DL, Galea E, Gavrilyuk V, et al. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol. 2002;51:694–702. https://doi.org/10.1002/ana.10206.CrossRefPubMed

368.

Shukla DK, Kaiser CC, Stebbins GT, Feinstein DL. Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients. Neurosci Lett. 2010;472:153–6. https://doi.org/10.1016/j.neulet.2010.01.046.CrossRefPubMed

369.

Kaiser CC, Shukla DK, Stebbins GT, et al. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol. 2009;211:124–30. https://doi.org/10.1016/j.jneuroim.2009.04.011.CrossRefPubMed

370.

Jojo GM, Kuppusamy G. Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer’s disease. J Clin Pharm Ther. 2019;44:337–48. https://doi.org/10.1111/jcpt.12808.CrossRefPubMed

371.

Kreiter DJ, van den Hurk J, Wiggins CJ, Hupperts RMM, Gerlach OHH. Ultra-high field spinal cord MRI in multiple sclerosis: where are we standing? A literature review. Mult Scler Relat Disord. 2022;57:103436. https://doi.org/10.1016/j.msard.2021.103436.CrossRefPubMed

372.

Cadavid D, Cohen JA, Freedman MS, et al. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler. 2017;23:94–105. https://doi.org/10.1177/1352458516638941.CrossRefPubMed

373.

Khan AR, Liu M, Khan MW, Zhai G. Progress in brain targeting drug delivery system by nasal route. J Control Release. 2017;268:364–89. https://doi.org/10.1016/j.jconrel.2017.09.001.CrossRefPubMed

374.

Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016;15:275–92. https://doi.org/10.1038/nrd.2015.21.CrossRefPubMed

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2022

A Response to: Letter to the Editor regarding “COVID-19-Related Burden and Risk Perception in Individuals with Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy: A Cross-Sectional Study”

Standard Dose Weekly Intramuscular Beta Interferon-1a May Be Inadequate for Some Patients with Multiple Sclerosis: A 19-Year Clinical Experience Using Twice a Week Dosage

Letter to the Editor regarding “COVID-19-Related Burden and Risk Perception in Individuals with Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy: A Cross-Sectional Study”

A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies

A Response to: Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”

Assessing the Clinical Meaningfulness of the Alzheimer’s Disease Composite Score (ADCOMS) Tool